Abstract
Acquired immunodeficiency syndrome (AIDS) is caused by human immunodeficiency virus (HIV) and remains a global health problem four decades after the report of its first case. Despite success in viral load suppression and the increase in patient survival due to combined antiretroviral therapy (cART), the development of new drugs has become imperative due to strains that have become resistant to antiretrovirals. In this context, there has been a continuous search for new anti-HIV agents based on several chemical scaffolds, including nitrogenated heterocyclic pyrrole rings, which have been included in several compounds with antiretroviral activity. Thus, this review aims to describe pyrrole-based compounds with anti-HIV activity as a new potential treatment against AIDS, covering the period between 2015 and 2020. Our research allowed us to conclude that pyrrole derivatives are still worth exploring, as they may provide highly active compounds targeting different steps of the HIV-1 replication cycle and act with an innovative mechanism.
Highlights
Acquired immunodeficiency syndrome (AIDS) is caused by the human immunodeficiency virus (HIV) and remains a global health problem four decades after the report of its first case [1]
AIDS therapy faces a series of drawbacks, mainly because its treatment is based on a cocktail that is difficult for patients to adhere to
This was confirmed with fostemsavir, which is the first antiretroviral drug used against HIV-1, and exhibits a pyrrole ring in its structure, showing the importance of exploring this nucleus
Summary
Acquired immunodeficiency syndrome (AIDS) is caused by the human immunodeficiency virus (HIV) and remains a global health problem four decades after the report of its first case [1]. Despite the success of viral load suppression and increased patient survival due to the correct administration of cART, the development of new drugs and formulations of combined fixed doses (CFDs), and long-releasing formulations with better patient adherence and tolerability to treatment, is imperative. These aspects are essential for decreasing the selection of drug-resistant viral strains, which are currently one of the Pharmaceuticals 2021, 14, 893.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
